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Special Feature: The Many Facets of
AIDS Research at Rockefeller
Twelve years after the start of the AIDS
epidemic, the plague remains unconquered.
Researchers at The Rockefeller University are
among the thousands of scientists worldwide
who are seeking new insights into the disease
and its causative agent, the human immuno
deficiency virus (HIV). In this issue's spedal
feature, senior science writer Susan Blum sur
veys AIDS research at the university and
shows how the roots of this research often
reach back to pioneering studies at
Rockefeller that predate the AIDS epidemic,
but that have proved remarkably relevant to it.
COVER NOTE-This cover of Search features a rare,
close-up look at HIV, the virus that causes AIDS. The elec
tron micrograph shows a mature HIV particle-magnified
about 640,000 times-attached to the "pit" in the surface
membrane. This state represents the first step in the recep
tor-mediated uptake of HIV.
Despite the abundance of printed matter on HIV and
AIDS, it was surprisingly difficult to locate a clear picture of
the virus. Our search took us to the Aaron Diamond AIDS
Research Center in New York, where we are indebted to its
director, David Ho, to the Seminars in Virology editorial
offices in London, and then to the Robert Koch lnstitut in
Berlin, where Hans Gelderblom was extremely helpful.
Gelderblom provided this micrograph, which originally
accompanied an article by R.I. Connor and Ho,
"Pathogenesis of Human Immunodeficiency Virus" that
appeared in Seminars in Virology (volume 3, 1992).
-The Editor
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n 1969, the Surgeon General of the United States declared tha� the

war against infectious diseases had been won. But clearly this procla

.., !

mation of victory was premature. With the appearance of HIV ..and the AIDS
pandemic, and the emergence of antibiotic-resistant strains of pathogenic
bacteria across the world, infectious diseases remain a fundamental threat to
all of humankind. This issue of Search features a comprehensive review of

. '.�l

AIDS research at The Rockefeller University, covering the many facets of the

' ··,(
'i

university's effort to better understand HIV and design new methods to

/,

The Rockefeller University was founded in 1901 as The Rockefeller

i '

Institute for Medical Research with the central mission of understanding the lethal secrets of disi.

,.

I

ease-causing microbes and us!ng this knowledge to design specific anti-microbial therapy. Since
· that time, this uhiversity has helped launch the antibiotic era and pioneer basic and clinical
research into the mechanisms of microbial pathogenesis. As the review of AIDS research at The
Rockefeller University demonstrates,. this historic commitment continues here today.
From the university's beginning, many of its research programs have stemmed directly from
the urgent publi� �ealth needs of New York City and other urban centers. This issue of Search
begins with a repo�t deliv�re·d at the uni_versity this past spring by New York City's top public

, health offidal,,M,argiret Hamburg, bn the interloc½ing challenges of AIDS, tuberculosis, and drug
;
addiction. In addition, on July 21, 1993, the university sponsored a workshop on a growing crisis
that has been exacerbated by the_ AIDS pandemic: the global emergence of antibiotic-resistant
strains of deadly bacteria. The meeting, which included some of the nation's leading experts on
public l}.ealth and)nfectious diseases, was the first step in a larger university program focused on
the probl�m of drn'g_jresistant mid-ob,es. The Rockefeller Univedity intends to continue to play a
leading role in �esearch into the mechani�ms of antibiotic resistance, the development of new
and more specific �ntimicrobial therapies, and the dissemination of information to physicians and
scientists working at other, institutions reg.:i.rding this growing medical crisis. With our strengths in
microbiology and molecular biol?gy, the clinical research capabilities of The Rockefeller
University Hospital, and our conra�ts with_ hospitaJs and, research institutions around the world,
The Rockefeller University is uriiq�ely positioned to continue 'its historic mission into the twentyfirst century.

� -'-_ v·cuJ
-_ . ·:: _ i'�.

,,f�.
t.

'\

. '·�:,

combat it.

'

Torsten Wiesel
President

....

TriP.le
Heatted
Disease
Threat

New York City
Health Commissioner
Addresses Three Related
Epidemics at Rockefeller
University Meeting

,1

In May 1993 the worlds of sci
entific research and public
policy came together for an
unusual meeting convened at
The Rockefeller University.
Sponsored by The Rockefeller
University Council-a. group
of 160 friends of the university

Y

ou cannot live in a city like
New York today without
being in some way affected
by the triple-headed disease
threat of drug addiction,
tuberculosis, and AIDS," Hamburg
began by telling the audience.
These three diseases are closely
interrelated-primarily because many
of the same factors underlie the inci
dence and spread of each: poverty,
unemployment, inadequate access to

where, Hamburg explained, the
reemergence of TB is connected to
the AIDS epidemic because people
whose immune function is seriously
compromised are more susceptible
to the disease. Hamburg estimated
that as many as 40 percent of the
city's TB patients are also infected
with HIV. With as many as a quarter
of a million New Yorkers already
HIV positive-and hundreds of thou
sands still at risk of AIDS-the num-

who promote public awareness
of the importance of basic
research in disease prevention
and treatment-the meeting
ad d ressed the increasingly
interconnected urban health
crises of AIDS , tuberculosis,
and drug addiction. For The
Rockefeller University, founded
in 1901 as the nation's first
biomedical research center,
the gathering reflected its long
st anding commitment to
understanding and conquer
ing infectious diseases. The
panel of speakers included
th ree leading Rockefeller
researchers-Dr. Vincent Dole,
Dr. Mary Jeanne Kreek, and
the late Dr. Zanvil A. Cohn

In her talk, Commissioner Margaret Hamburg stressed that society can no longer afford to neglect the
burgeoning and interconnected urban health crises of AIDS, tuberculosis, and drug addiction.

Margaret A. Hamburg. The

health care, substandard housing,
and homelessness. And this connec
tion is not unique to New York City.
"Poverty is a primary force fueling
the crisis in public health throughout
the country," Hamburg said.

work of the three Rockefeller

Three Overlapping Epidemics

as well as New York City's
Health Commissioner, Dr.

investigators is covered in the
article that begins on page 8
(see The Battle Against AIDS).
Following is a discussion of the
remarks made by Hamburg.

The United States as a whole has
experienced a 143 percent increase
in the incidence of tuberculosis since
1980, and New York's case load is
disproportionately high, accounting
for about 15 percent of the nation's
cases. Poverty alone cannot account
for this resurgence. Here, as else-

ber of people susceptible to TB
infection is significant.
To make matters worse, TB is
much harder and more complex to
treat in people with AIDS. "Even
more alarming," according to
Hamburg, "the recently documented
outbreaks of multidrug-resistant TB
in New York City have dispropor
tionately involved HIV-infected
individuals."
Even without the additional bur
den of TB, Hamburg said, AIDS will
continue to take an enormous toll. It
is already the leading cause of death
among both men and women aged

5

:t:Wenty-five to forty-four in the city.
The combination of AIDS and TB is
especially deadly.
Fueling both of these overlapping
epidemics is the problem of drug
addiction. The use of shared 'intra
venous, needles is a major m�de of
t�;;ihsmission of HIV; in , addition,
drug addicts often engage: in uns:afe
sex'ual 'practices. The r,esult is that
addict�, their partners, and. their
unbprn children are p lated at
increased risk for AIDS and TB.
l� New York, with approximately
200,00,0 intravenous drug users, IV
drug u,se is linked either directly or
through a sex partner's IV drug use
to !the, majority of new HIV infection�
in men and women and is responsi
ble for almost 80 percent of pediatric
AIDS cases,' Hamburg asserted.' Many
of the h�meless
are al.s o HIV
positive and
"There is a substantial and
addicted
to
growing population which
drugs.
These fac
is either already suffering
tors make it
from a combination of TB,
more difficult
to treat and
AIDS, and drug addiction,
cure TB infec
or is at increased risk
The y
tions.
have also con
for disease."
tributed to the
rise in drug
resistant strains.
"Partial or non-completion of the six
to nine months normally required to
treat and cure TB fosters recurrence
of infe<;tious TB and the emE!rgence
of dr�g-resistant strains. Those indi
viduals ._can then transmit; 9rug-resis
tanf 1:'B to othe.rs)1nd 'will require
ad;9Jt'ional and,_c9s{lyJreatrri�nt t�em-;. ..
sef�es:" the co'mr£"iisfuiler'1ipiairi�d. -:·
c Furthermore, many of these indi
viduals obtain temporary housing in '
911,e of the city's networks.' of shelters
a_�d periodically serve time in the
city's· criminal justice system. Many
�f the shelters and jails are "poorly
ventilated, overcrowded congregate
settings-ideal breeding grounds for
thi: ,spread of an airborne disease
li�e TB;'' she said.
, ,, ffamburg was blunt in her assess
ment. "There is a substantial and
0

:J
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growing population which is either
already suffering from a combination
of TB, AIDS, and drug �ddiction, or
is at incre.a sed risk for disease
because of social circumstance·s,
weakened health status, and height. ened risk of exposure."

Strains in the System

These, three epidemics .place an
"almost unbearable strain on an
�lready overburdened health care
system," said Hamburg, who oyer
sees a department with a $300 mil
lion budget and more than 4,000
employees. Countless New Yorkers,
manY; without health insurance or
access to routine care, many home
less, drug addicted,, and. suffering
from AIDS and TB, must use the
emergency rooms as their provider
of first and last resort. This leads to
spor�dic treatment, inadequate med
ical care, and "terribly high burnout
rates" for medical staff.
In addition, the commissioner
said, our failure to recognize the vital
role of public health and our focus
on treatment rather than prevention
has exacerbated these problems:
"The infrastructure of public health
has been terribly undermined over
the past decade as a result of contin
uous budgetary cuts and thoughtless
consolidation of agencies and pro
grams." As a re�ult, many core func
tions of public - health, such as dis
ease surveillance and epidemiology,
outreach, prevention, education,
infectious disease control, _protection
against environmental threats to
health, and quality assurance have
been Compromised.
This Jailure has cQntributed to the
ree-mergence. of TB �nd other dis
eases once deemed eradicated or
under control. Once effective anti-TB
drugs were introduced.
, there was no
0
further effort to li mit r:iosocomial
spr;ead or to moqit�i;' TB patients
- aft�r_ discharge. TB trea�menrt pro
grams; like casei rrfanage'ment and
, supervised tht;rapy, never, r�'ceive'd
enough supp�}ft. In addition, aware�
ness and trairiing about 1:B, along
with its appropriate management
and treatment, diminished. This

ham-

pered the ability to rapidly and effec
tively diagnose and treat TB, and
resulted in fewer facilities for TB
control.
"A nd so,'" Hamburg concluded,
"despite full kn'�wledge of how to
prevent, control_;._and even cure
TB; we are Stru�gling to cope with
restlrgent di$easJ". ";·,

P�eve·ntion · and Public Health
k

.'

i

'

Hambui:g ,em'phasized that we
can no longer af�9,rd the costs of
neglecting medi<5:al problems until
they pose an immediate threat to
pµbli,c health.. "W� ,spend billions of
dollars oh medical care that could
ha've been ave;rted had we been will
ing ·to invest in prevention. For
1
iilstartce, · drug adpiction costs this
city countless ;d�hars 'in lost produc
tivity, law �nfor�:e,ment efforts, and
health care co,sts�not to mention
the terrible cos� g.aid in wasted lives,
Yet there'are fe��� than 44,000 drug
treatment slots' available to serve
well over one_.hqlf million New
Yorkers who may, need drug'treatment.'
, In the f�ce of' th�se challenges;
H;irt1burg said.�Ei' must reaffirm our
co�mitment t� the goals of preven
ti�n .and to pub)'iis= health as well as.
being IT).Ore creMi:Ve in devising
methods to tackle ·today's public
health threatsi Tq �ombat these __ dis.:
eases effectively, we must acknowl�
'edge economic realities. In certain
instances this may mean providing
stable housing or supportive sociat
services-counseling, entitlement
assistance, life skills training, and
linkage with substance abuse and
alcohol treatment programs.
Both AIDS and drug addiction are
illnesses rooted in individual behav
iors, Hamburg said, and the develop
ment and treatment of active TB are
directly influenced by an individual's
ability to comply with prescribed
treatment.
"Clearly, better understanding of
how to reduce dangerous behaviors
(
like intravenous drug use and unsafe
, sex, �nd ,how to increase treatment
' compliance are critical to our efforts
to contain these diseases," she said.
, "Yet our investment in behavioral
'

•
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research has been woefully inade
quate."

Need for Basic Research

The commissioner emphasized
that research is an essential compo
nent of public heath. She said: "It is
. to research that w,re turn for new
drugs, better delive'ry ·systems, new
diagnostics that are faster, cheaper,
and easier to use, improved thera
peutic interventions, and, if we are
lucky, vaccines."
In particular, more basic research
into the nature and mechanisms of
these diseases is paramount. "We
need to increase our knowledge of
the nature of the tuberculosis organ" ism and the body's immune response
to it so we can employ the best
strategies for diag;nosis and treat-

ment. We desperately need t:o devel
op new drugs and new intervention
strategies.
"Simultaneously, our efforts to
better understand AIDS �ust contin
ue and expand. We have not. yet
grasped the full nature of the AIDS
virus_ or the immune response to
infection with this virus; nor have we
identified drugs that can safely and
effectively kill the virus or ihterrupt
·its replication. And of ·course, we
must continue to support efforts to
create an effective vaccine."
Research into the nature and
treatment of addiction h�s- perhaps
been th� most woefully lacking of
all, �amburg added, a_ nd,1 concerted
efforts must move· forward on all
these 'fronts.
Hamburg reiterated that research

must be part of a much broader
effoi-t. 1 "We must make certain
that we continue
to adyocate force'...
fully for a robus·t
"We �ave not yet grasped
public health systern.
, We must
the full nature of the AIDS
.
i
strengthen our
virus or the immune
commitment to
prevention ef
response infection with
forts. And we
this vi,rus; nor have we identi
remain
must
fully cognizant
fied dwgs that can safely
of thrc social
and effectively kill the virus
forces that propel
these deadly epi
or interrupt its replication."
demics. As a city
and as a nation,
we can no lo.nger afford the consequences of
negle�ting these concerns."

to

•...�.
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Speakers at a panel on urban· health crises held at The
,Rockefeller University thi·s,spririg included (from left to
right) Professor Emeritus Vincent Dole, New York City
Commissioner of Health Margaret Hamburg, Associate
Professor Mary Jeanne Kreek, and the late Professor and
Vice President for Medical Affairs Zanvil Cohn.
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BATTLE AGAINST
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V

by Susan Blum

iruses are nature's canniest
pathogens. Extraordinarily
small, they must of neces
sity travel light, packing only
their genes wrapped up in a protein
coat. Most of the genetic information
they carry is devoted to accomplishing
their modest goals: reproducing within
a cell and introducing themselves into
other cells. To do their dirty work,
viruses mobilize the machinery of the
cells they infect to produce all the pro
teins they need to survive, thrive, and
propagate.
Of all these efficient intracellular
parasites, none is more clever than the
human immunodeficiency virus
(HIV)-the virus that causes AIDS. Not
only does HIV commandeer the body's
protein-production equipment, but it
disarms its defenses, as well. HIV's
prime targets are cells central to
immune-system functioning-the
helper T cells that turn on and amplify
many immune-system responses, and
the macrophages that help rid the
body of pathogens and the cells they
infect. By disrupting immune-system
functions in numerous ways, infection
with HIV sets the stage for the diseases
that eventually claim the lives of peo
ple with AIDS, including opportunistic
infections (such as Pneumocystis
carinii), rare cancers (such as Kaposi's
sarcoma), and tuberculosis.
The devastation caused by HIV is
overwhelming, with no end in sight.
The World Health Organization
(WHO) estimates that more than one
million people are infected with HIV in
the United States, and another fourteen
million are infected elsewhere around

The human immunodeficiency virus (HIV) turns infect
ed cells into factories for new viral particles. This
electron micrograph gives a dramatic view of new
viruses (small black dots) assembling at the surface
of a cell and budding from it. (Photo courtesy of
Associate Professor Gilla Kaplan.)

Susan Blum is senior science writer in The
Rockefeller University Public Affairs Office.
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the globe. More than three-quarters
of all current HIV infections are in
Africa, but the epidemic is now
growing most rapidly in Asia where, it
is predicted, the number of new
infections will soon outpace those in
Africa. WHO estimates that by centu
ry's end, the total number of HIV
infections will reach forty million.
The world desperately waits for
an end to this plague, but as yet
there is neither a cure for those
already infected with HIV, nor a vac
cine to protect those who are not. As
researchers strive to devise better
strategies to treat and prevent AIDS,
they face many unanswered questions.
How, for instance, does the virus
wreak its havoc on the immune sys-

tern? Can the body's defenses be bol
stered once infection occurs? Why do
some people succumb to the virus
sooner than others? What types of
immune responses must be elicited
by a successful vaccine or immune
therapy? At what stages might the
viral life cycle be blocked? What
functions are served by the various
HIV genes? What measures can be
taken to prevent the spread of infec
tion with HIV?
Researchers at The Rockefeller
University are among the thousands
of scientists worldwide who are ask
ing these questions-and others-in
an attempt to conquer AIDS. They
bring to their quest a unique combi
nation of perspectives and scientific

talents to attack HIV from all quar
ters, including molecular biology,
virology, infectious diseases,
immunology, and patient-oriented
studies. Often, the roots of their
research reach back to pioneering
studies begun decades ago in
1
Rockefeller labs-studies that
predate the AIDS epidemic, but that
have proved remarkably relevant
to it.
In the pages that follow, Search
chronicles some of the AIDS
research being conducted on cam
pus. The scope and variety of these
studies reflect the many challenges
scientists face as they try to outsmart
one of the most savvy pathogens
they have ever had to confront.

Confronting HIV: The Immune System versus the Virus
Researchers in the Cohn-Steinman laboratory explore hovv the immune
system responds to HIV and hovv that response might be bolstered

D

espite more than a decade of
research, scientists studying
AIDS still do not know in
detail how the immune system
responds-and how it is impaired
w hen confronted with HIV.
Underlying this mystery is the extra
ordinary complexity of the immune
system itself. Countless details
remain to be learned.
Many features that are known so
far about the immune system come
from the pioneering research of sci
entists in the Rockefeller laboratory
headed by Ralph Steinman and, until
his recent death, Zanvil Cohn. There,
scientists are combining basic lab
research with medical studies of spe
cific diseases conducted at The
Rockefeller University Hospital.
Among the diseases under investiga
tion are AIDS and tuberculosis (TB),
a disease often associated with AIDS
and exacerbated by it.
The laboratory's clinical and basic
studies cover a wide range of ques
tions relevant to AIDS, including the
function of specific immune-system
cells, their regulation, the interac-

tions among them, their beneficial
and harmful effects, and the ways
those effects might be manipulated
to treat disease.
The researchers focus on a type
of immune-system response known
as cell-mediated immunity. As its
name implies, this arm of the body's

One aim of the researchers
is to boost beneficial
immune-system responses
to HIV Another is to
diminish responses that
might be harmful.
defense repertoire pits immune-sys
tem cells directly against cells in the
body that have been infected with
bacteria or viruses (see illustration,
page 13). The other arm of the
immune system-known as humoral
immunity-mobilizes proteins called

antibodies, which travel through .the
blood and the lymph system and
neutralize pathogens before they can
infect cells.
One type of immune-system cell
is the macrophage, a cell that was a
special research interest of Cohn's. In
fact, his work was so central to the
understanding of macrophages that
Cohn was widely acknowledged to
be the "dean" of macrophage stud
ies. Macrophages kill in a number of
ways, but their primary modus
operandi is phagocytosis-a process
of engulfment that sequesters and
kills both free-floating microbes and
the cells they infect.
T cells, or lymphocytes, are
another class of immune-system
cells, whose various names reflect
the specialized proteins they sport
on their surfaces. "Cytotoxic" CDS T
cells, for instance, engage in cell
killing. CD4 T cells, or "helper" T
cells, orchestrate a wide range of
defensive responses through their
effects on many other immune-sys
tem cells, including macrophages,
CDS T cells, and the cells that make

,....,
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Above, Associate Professor G iIla

Kaplan and Postdoctoral
Associate Andre Moreira study
how the drug thalidomide inhibits
the activation of HIV. Below,
Professor Ralph Steinman con
ducts research with Postdoctoral
Associate Melissa Pope on den
dritic cell-COB T cell interactions,
and with Clinical Scholar Ian Tang
'on the effect of interleukin-2 on
COB T cell.s.

1 1

antibodies. The catastrophic effects
of AIDS are largely due to the fact
that HIV infects these CD4 T cells,
which are so vital to immune-system
functioning.
Dendritic cells, whose existence
was discovered by Steinman and
Cohn, are yet another type of
immune-system cell. Dendritic
cells serve as sentinels that
scout out "foreigners"
such
as
invading
pathogens, and pre
sent fragments of
these foreigners
(called antigens)
to CD4 and CDS
T cells, which
can then re- /.
spond. Natural
killer cells, or
NKs, (many of
whose functions
were elucidated
in the Cohn
Steinman lab) and
lymphokine-activate d killer cells, or
LAKs, are additional
types of immune-system
cells that can also destroy
infected cells in the body.
Goading the various immune
system cells into action are a wide
range of proteins called cytokines.
These hormone-like substances are
produced by certain immune-system
cells (notably CD4 T cells) and, in
complicated biochemical feedback
loops, induce immune cells to devel
op, proliferate, and become activat
ed. Numerous cytokines have been
under investigation in the lab for
years, with particular emphasis on
patient-oriented studies exploring
how cytokines may modulate the
immune response and affect disease
states.
For example, a pioneering series
of AIDS studies began in 1990, using
a cytokine named interleukin-2 (IL2). IL-2, produced by CD4 T cells,
stimulates a wide range of other
immune cells, such as CDS T cells,
NKs, LAKs, and CD4 T cells them
selves. Ever since genetic engineer
ing techniques first made it possible

to manufacture "recombinant" IL-2,
the Rockefeller researchers· have
been using the engineered product
to amplify immune response in a
number of diseases, first with leprosy
and now also with TB and AIDS.

"Given that AIDS is characterized by
a depletion of CD4 T cells-the very
cells that produce IL-2-we reasoned
that IL-2 therapy might prove useful
in the treatment of people .with
AIDS," says Gilla Kaplan, a scientist
in the lab. The therapeutic studies,
conducted at The Rockefeller
University Hospital, used low doses
of the genetically engineered IL-2,
unlike the higher, toxic doses of IL-2
used by researchers elsewhere to
treat cancer.
The results of the lab's first,
short-term trials were encouraging:
individuals who received IL-2
showed an increase (in some cases)
or stabilization (in others) of CD4 T
cell count-a clear benefit for those
infected with HIV. They also showed
an increase in the number and activi
ty of both NKs and LAKs-increases
Dendritic cells scout out foreign invaders and
present them to other immune-system cells.
which can then respond. Above, T cells cluster
around a dendritic cell.

which might help eliminate HIV
infected cells, cells infected with
opportunistic pathogens, or both.
Longer-term- studies of the effects of
low doses of IL-2 in patients with
AIDS and/or TB on CD4 T cells and
nonspecific killer cells are now getting
under way directed by Kaplan.
In a related line of patient-ori
ented AIDS research, studies
of IL-2's effects on another
component of the cellu
lar immune system
CDS T cells-are
under way under
Steinman's direc
tion. He and his
colleagues have
long been exploring the func
tion of these
Unlike
cells.
NKs and LAKs,
which respond to
a wide range of
antigens,
each
"clone," or group,
of cytotoxic CDS T
cells is genetically pro
grammed to respond to
just one of a pathogen's
antigens.
Steinman explains, "HIV mutates
very rapidly, allowing it to outfox the
antibody limb of the immune system.
But it is much harder for HIV to
escape killer CDS T cells, since they
recognize parts of the virus that do
not mutate." Thus, he and his col
leagues are eager to see whether
boosting CDS T cells' activity might
improve the body's ability to rid
itself of HIV-infected cells.
Steinman also plans to explore
whether interactions with dendritic
cells might boost CDS T cell activity.
Dendritic cells normally present anti
gen to both CDS and CD4 T cells; in
so doing, they stimulate those cells
into action.
Over a year ago, Steinman and
his colleagues showed how dendritic
cells can be key players in the loss
of CD4 T cells that is a hallmark of
AIDS. They found that intact HIV
"hitchhikes" on dendritic cells that
carry the antigens of other pathogens

THE CELLULAR IMMUNE SVS_TEM

------ Dendritic cells

Helper T cells (CD4 T Cells)

These cells serve as sentinels to scout
out "foreigners" such as invading
pathogens. They present fragments of
these foreigners (called antigens) to CD4
and CDS T cells, which can then respond.

These cells play a key role in the body's
defense system. CD4 T cells orchestrate
a wide range of immune responses. They
stimulate CDS T cells and other killer
cells, macrophages, and the cells that
produce antibodies.

Interferon gamma

Interleukin 2 (IL-2)

This is a hormone-like substance, or
cytokine, that is produced by CD4 T cells
and stimulates macrophages and other
immune-system cells.

IL-2
Interferon
gamma

IL-2

This is a hormone-like protein, called a
cytokine, that is produced by CD4 T cells.
IL-2 stimulates and activates a wide vari. ety_of immune-system cells, including
CD4 T cells themselves.

Macrophages

These cells engulf and
kill pathogens.

TNF-alpha

TNF-alpha

This is a cytokine that is produced by
macrophages and other immunesystem cells. TNF-alpha prompts a num
ber of beneficial immune-system respons
es, but too much of it can be harmful.

to CD4 T cells. As the CD4 T cells
cluster around the dendritic cell and
are activated by it in response to the
antigen, they are also infected with
the bystander HIV. Then, the CD4 T
cells become a syncitium-one giant
cell with many nuclei. The result: an
"explosive" CD4 T cell infection and
massive cell death.
Ironically, though, another aspect
of dendritic cell functioning may
actually help the body fight infection
with HIV. In studies at The
Rockefeller University Hospital,
Steinman and his colleagues plan to
remove dendritic cells from people
infected with HIV, manipulate the

cells in the test tube so they present
particular HIV antigens (not the
whole virus), and then reintroduce
the cells into the infected individual
in an attempt to amplify CDS T cell
response. The researchers believe
they will be able to manipulate the
dendritic cells so that they present
the HIV antigen only to CDS T cells,
and not to CD4 T cells.
While one aim of the lab's
research is to boost beneficial
immune-system responses against
HIV, a parallel aim is to diminish
responses that may be harmful. One
such harmful response is the over
production of TNF-alpha, a potent

These cells attack other cells that are infected
by viruses or bacteria. Some killer cells (CDS T
cells) carry the CDS protein, which helps the
cell reco.gnize pathogens. Other killer cells,
known as natural killer cells and lymphokine
activated cells, do not carry the CDS protein.

cytokine produced by macrophages
and other immune system cells when
viruses and bacteria invade the body.
Some TNF-alpha is vital for the
body's defensive maneuvers, but too
much of the substance can produce
debihtating fevers, weight loss, and
fatigue that seriously impede a per
son's ability to combat disease.
Patients with TB produce too much
TNF-alpha. So do patients with AIDS,
as a result of their opportunistic
infections and, perhaps, as a result
of infection with HIV itself.
The scientists' studies of TNF 
alpha have their roots in the lab's
long-standing interest in leprosy.

Illustrations by Terese Winslow .
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THE STRUCTURE OF HIV

p17
p24

p7 and p9
gp41

Reverse transcriptase
Viral envelope

RNA

The material of which HIV's genes are made.
RNA is a close molecular cousin of DNA, the
more common genetic material.
Reverse transcriptase

The viral enzyme that makes a DNA copy of
HIV's RNA genes.
Viral envelope

The virus's fatty membrane coat. It is derived
from the membranes of the cells that HIV
infects.

14

gp120 and gp41

Two proteins embedded in the virus's fatty
coat (also called its envelope). The proteins
are produced from a precursor protein called
gp160. gp120 binds to CD4 receptor proteins
on the surface of helper T cells and
macrophages. In ways that remain unknown,
gp41 is involved in the fusion of the virus
with the cell it infects.

p17 and p24

Two proteins coded for by an HIV gene
called gag. Molecules of p17 surround the
inner portion of the HIV envelope. Molecules
of p24 make up the capsid, or core - the
structure that surrounds the virus's RNA
genes.
p7 and p9

Two proteins coded for by an HIV gene
called gag. They are both believed to bind to
the virus's RNA genes.

While treatment for leprosy is effec
tive, it can lead to serious side
effects. For a quarter of a century,
doctors successfully combated those
side effects with the drug thalido
mide, although they did not know
why the therapy worked. Recently,
however, research by Kaplan and
her colleagues disclosed that thalido
mide selectively inhibits TNF-alpha,
while leaving other beneficial defen
sive responses intact. They have
recently begun clinical trials of
thalidomide to combat the effects of
excess TNF-alpha in people with
AIDS and/or TB. The initial results,
which include dramatic weight gain
and reductions in fever, have been

extremely promising.
The Rockefel ler University
researchers' most recent studies indi
cate that thalidomide may prove use
ful in combating not only the symp
toms of AIDS, but the replication of
its causative virus, as well. As it turns
out, TNF-alpha is an extremely
potent trigger for the activation of
HIV genes that have been integrated
into a host cell's genes and lie dor
mant there. (See illustration, page
18.) When TNF-alpha is produced in
response to infection (such as with
an opportunistic pathogen), the dor
mant HIV genes are turned on at the
same time as immune-cell genes that
are mobilized to fight the infection.

In this way, HIV "parasitizes" the
regulatory mechanisms of immune
cells for its own purposes.
Test-tube experiments by Kaplan
and her colleagues have already
indicated that thalidomide can stop
HIV replication in certain laboratory
cell lines, as well as in blood cells
taken from patients and grown in
culture. In ongoing clinical trials at
The Rockefeller University Hospital,
the researchers are now administer
ing thalidomide to people with AIDS
(with and without TB) to further
explore the promising indications
that thalidomide might provide an
effective new therapy in the fight
against AIDS.
f

A Budding Subject: Hovv HIV Escapes from the Cell
In the Aderem lab, studies of interactions betvveen proteins and mem
branes may yield strategies that keep HIV from assembling vvithin an
infected cell and moving out to infect others

V

iral infections progress when
viruses harbored within host
cells multiply, leave, and go
on to infect other cells. Before HIV
can leave a cell, one of its proteins
called pSS gag (or pSS, for short)
must get to the host cell's mem
brane. There, the virus assembles,
with pSS providing the scaffold.
Once assembled, the virus buds off
from the membrane, and pSS is
cleaved to form a number of pro
teins, including p24, pl 7, p9, and
p7. (See illustration, page 14.)
In this process of assembly, as in
many other process
es, HIV hijacks the
host cell's machinery
for its own purpos
es. It induces a cel
lular enzyme to
place a specialized
substance on pSS.
This substance, cal
led myristic acid, is a
fatty molecule that
decorates at least
fifty cellular proteins
and helps them bind
to membranes. It
Associate Professor Alan
Aderem and Postdoctoral Fellow
Jennifer Darnell are pursui,ng
ways to keep HIV from assem
bling within infected cells.

Because HIV hijacks the
cell's own machinery,
many anti-HIV strategies
can impair the cell's
normal functioning, too.
The goal is to find a strat
egy that is specific to HIV.

serves the same purpose for pSS.
Myristoylation-the addition of
membrane-attaching myristic acid to
proteins-has long been a subject of
interest for Alan Aderem. As a
researcher in the Cohn-Steinman lab,
while investigating how immune
cells called macrophages respond to
external messages, he discovered
two myristoylated proteins called
MARCKS and MacMARCKS. These
proteins are still under intensive
study in his own lab, which he has
headed since 1991.
MARCKS is now known to occur
in virtually all cell
types, while Mac
MARCKS' distribu
tion is more limited.
The specific func
tion of these two
"MARCKS brothers"
varies among cell
types, but in general
they appear to facili
tate interactions
between cellular
membranes and the
cytoskeleton-the
filamentous protein
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backbone that gives a cell shape and
allows it to move.
In macrophages, such mem
brane-cytoskeleton interactions are
vital for phagocytosis and endocyto
sis-the processes by which the cells
engulf and incorporate particles such
as pathogens and dead or dying
cells. The interactions may also be
vital for viral budding-a process
which, Aderem points out, appears
to be the opposite of endocytosis. In
one case, a particle-such as a
pathogen-must be brought into the
cell and somehow maneuvered
through the cytoskeletal framework.
In the other case, a particle-the
virus-must make its way out
through the cytoskeleton.
This intriguing analogy has led
Aderem and his colleagues to add
studies of HIV assembly and bud
ding to the roster of projects under
way in their lab. They are pursuing
the subject in the two main cell
types infected by HIV: CD4 T cells

and macrophages.
It is well established that newly
assembled HIV buds off from the
CD4 T cell's surface membrane,
thereby killing the cell, but what
happens in macrophages-where
the virus does not bud outward-is
less w�ll understood. One model
holds that in macrophages myristoy
lated p55 binds to internal mem
branes. The virus then assembles
and "buds" into the compartments
the membranes surround. Thus,
macrophages can serve as HIV reser
voirs. When these cellular storehous
es eventually die, they release their
burden of infectious virus. In
the brain, where specialized
macrophages called microglia are
infected by HIV, such a process may
cause the dementia that is often a
symptom of AIDS.
What might direct myristoylated
p55 to different membranes in differ
ent cell types? Aderem and his col
leagues speculate that these proteins

might link up with specific receptors
studding the membranes in question.
They are currently hunting for these
receptors, bolstered by the knowl
edge that they have already discov
ered candidate receptors for the
myristoylated forms of MARCKS and
MacMARCKS.
If receptors for myristoylated p55
can be found, it might eventually be
possible to block them, thereby fore
stalling p55-membrane interactions.
Such interventions would effectively
stop HIV in its tracks, since the virus
would no longer be able to assemble
and bud. Experiments elsewhere
have already shown that preventing
the myristoylation of p55 also blocks
HIV budding. But this strategy is not
feasible for long-term therapeutic
use, since it targets a cellular enzyme
that controls many myristoylation
events vital for normal cell function
ing. "The goal," says Aderem, "is to
block a pathway that is absolutely
specific for the virus."

Fateful Paths: Hovv CD4 T Cell Function Goes Avvry in AIDS
Studies of T cell development and function in the Choi lab help illuminate
the depletion of CD4 T cells, the immune-system orchestrators vvhose loss is
so catastrophic in AIDS

A

s the disaster of AIDS attests,
humans cannot survive with
out properly functioning T
cells. But the critical importance of
these cells is much better under
stood than the mechanisms b y
which they obtain, and maintain,
their
defensive
capabilities.
Yongwon Choi is investigating how
T cells develop and function.
Ultimately, his studies may also shed
light on how their function goes awry
in AIDS.
During development, immature
T cells undergo a complicated
process of selection that allows only
some of them to survive. This com
plex enterprise involves the presen
tation to T cells of "self-antigens"
fragments of proteins that belong to
the body's own tissues. In the course

of selection, Choi explains, "some
developing T cells see self-antigen
and live, while others see self-anti
gen and die. It's a very intriguing
contradiction."
Choi is pursuing the cellular sig
naling events at the heart of this
contradiction, but his search is com
plicated by the difficulties of study
ing cells within developing mam
mals. One way he circumvents this
problem is to study other immune
system phenomena that may shed
light on T cell development.
As part of his studies, Choi is
investigating how CD4 T cells (the T
cells depleted in AIDS) interact with
a class of antigens known as super
antigens. Rather than rousing one in
10,000 or 100,000 helper T cells, a
superantigen goads 25 or 30 percent

of them into action. Oddly enough,
once the superantigen-stimulated T
cells have proliferated, they some
times subsequently become inactive
or self-destruct through a cell death
program known as a poptosis-a
process that recalls the death of T
cells during development.
When Choi was a postdoctoral
fellow, he discovered that a mouse
retrovirus called MMTV encodes a
protein that can act as a superanti
gen. When MMTV is incorporated
into an animal's chromosomes and
passed to the next generation, the
superantigen it encodes can provoke
the destruction, or deletion, of a
whole subset of T cells in the devel
oping animal. But if MMTV infects a
mouse after it is born, the superanti
gen it encodes can cause the mas-

......
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sive T cell proliferation characteristic of that
induced by other superantigens. Like those
superantigens, MMTV can also cause subse-·
quent T cell inactivation or death.
Might HIV-which, like MMTV, is a retro
virus-also encode a superantigen? According
to Choi, the evidence is suggestive, but mixed.
Far more research is required to settle the

Many researchers believe that
only a small proportion of CD4 T
cells are infected with HIV.
Why, then, do so many CD4 T
cells eventually die?
question, and he hopes soon to begin such
investigations. But should it turn out that HIV
does not itself encode a superantigen, these
immune-system superstimulators may still be
involved in AIDS. "Many of the viruses already
present in the body may encode superanti
gens that are only produced when HIV is also
present," says Choi. These activated superanti
gens could contribute to the CD4 T cell deple
tion seen in AIDS.
Whatever the ultimate role of superanti
gens in AIDS may turn out to be, Choi is
hopeful that his fundamental interest in T cell
development may yield clues about the dis
ease. For instance, though the issue is current
ly being debated, many researchers (Choi
among them) believe that only a small
proportion of CD4 T cells are infected with
HIV. Why, then, do so many CD4 T cells even
tually die?
Choi points out, "If you present antigen to
CD4 T cells from people who are HIV nega
tive, the cells that are primed to recognize the
antigen proliferate. But if you do the same
thing with uninfected CD4 T cells of people
who are HIV positive, the cells primed to rec
ognize the antigen die, rather than proliferate."
This paradox recalls the question that
intrigues Choi about T cell maturation during
development: Why do some T cells see self
antigen and live while others see self-antigen
and die? The phenomena look to Choi like
two sides of the same coin. The challenge is
to figure out how the coin is minted.
Assistant Prnfessor Yongwon Choi (right) and
Postdoctoral Associate Jang Won Choi are
researching the mechanisms of T cell
development and death.
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THE LIFE CYCLE OF HIV
From Infection of the Target Cell to the Budding
of Nevv Viruses From the Cell
1

HIV virus

1. HIV attaches to a protein
receptor, called CD4, found on
the surface of helper T cells and
macrophages.

2. The virus fuses with the host cell's
membrane and enters the cell.
3. The virus sheds its protein coat.
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4. A viral enzyme called reverse
transcriptase copies the viral
RNA into DNA.
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7. The virus commandeers the
cell's protein-production machin
ery to "translate" the information
in viral mRNA into viral proteins.
Protein-production machinery

\

Viral RNA genes

8. The virus assembles itself andu
buds out of the cell.
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Revealing Differences: Studying the Human Retroviruses
Small in number but great in impact, the retroviruses that infect humans
including HIV-are the subject of study in the Hall lab

N

umerous retroviruses infect
animals, but only four are
known to infect human
beings: the human immunodeficien
cy viruses types 1 · and 2 (HIV-1 and
HIV-2) and the human T cell
leukemia viruses I and II (HTLV-I
and II). Virologist William Hall spe
cializes in the study of these human
retroviruses.
A physician as well as a basic
researcher, Hall brings a special per
spective to his studies. For instance,
in studying HIV-positive intravenous
drug abusers in the New York City
area, he and his colleagues discov
ered that about 13 percent of them
are also infected with either HTLV-I
or HTLV-II, with the vast majority
being infected with HTLV-II. A num
ber of previous studies have shown
that people infected with both HIV
and HTLV-I progress to full-blown
AIDS and deteriorate faster than the
average patient. In contrast, Hall has
noted, the course of disease tends to
progress more slowly than average
in those co-infected with HIV and
HTLV-II.
What might contribute to these
differences? Hall and his colleagues
have found that HTLV-II infects CDS,
or cytotoxic, T cells, unlike HIV and
HTLV-I, which both infect CD4
T cells, otherwise known as helper
T cells.
Profound differences in immune
system responsiveness may result
from these different patterns of infec
tion. As Hall explains, "Because
HTLV-I and HIV both infect the same
cell population, they may well acti
vate each other's replication," there
by hastening the depletion of crucial
CD4 T cells.
On the other hand, Hall points
out, CDS T cell counts are actually
higher than normal in people who
are infected with HTLV-II, and this
may somehow bolster these persons'

abilities to fight back when they are
co-infected with HIV.
Hall and his colleagues plan to
pursue the role CDS T cells may play
in combating AIDS. He is intrigued
by studies conducted in San
Francisco showing higher-than-nor
mal CDS T cell counts in a group of
homosexual men who are long-term
survivors-that is, people who have
remained well for over a decade,
despite being infected with HIV. The
men are not infected with HTLV-II,
and the cause of their higher-than
normal CDS T cell counts is not yet
known. But the California re
searchers studying the men report
that their CDS T cells produce an as
yet unidentified substance that
inhibits HIV replication.
Though interested in these
reported results, Hall remains cir
cumspect. "We really don't know

Associate Professor William Hall (left} and
Postdoctoral Fellows Shi Wei Zhu (center} and
Takayuki Kubo study the human retroviruses.
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w hat role C DS T cells may be
playing, but we want to find ·out,"
he says.
He and his colleagues are also study
ing HIV itself. While
investigating
how
HIV's genes become
integrated into the
genes of the host cell,
they found that an
important part of this
process involves �the
activity of an enzyme,
called a topoiso
merase, that is encod
ed b y the HIV gag
gene-the same gene
that codes for a num
ber of the virus's
structural proteins.
They are now study
ing a number of inhib
itors of the topoiso
merase to explore
how they might be
used as antiviral
agents. In another
research direction, they are studying
the process by which a viral precur-

People infected witn
both HIV and another
retrovirus called
HTLV-1 progress to
AIDS and deteriorate
faster than the aver
age patient, while the
course of disease
progresses more
slowly than average
in those co-infected
with HIV and HTLV-11.
The question is why.
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sor protein called gp160 is processed
into HIV's two envelope proteins, a
step that is necessary to complete
the virus's. life cycle. They hope their
research will disclose new ways to
inhibit this process.
They are also exploring the pos
sibilities for an oral vaccine against
AIDS. Using HTLV-I as a model, they
have identified regions of viral pro
teins that provoke neutralizing anti
bodies-antibodies that attach them
selves to the virus and prevent it
from infecting cells. They plan to
link peptides (short proteins) mim
icking these regions to the B subunit
of cholera toxin, or CTB, which can
be used as a vaccine delivery vehi
cle. CTB binds avidly to a molecule
found in abundance on the surface
of mucosal cells, the cells that line
body cavities such as the mouth, gut,
and genital tract. As a first step, Hall
and his colleagues will test this
model vaccine in rats, to see how
well it evokes two different kinds of
immune responses-one that works
at mucosal surfaces, and one that
operates systemically throughout
the body.

A Slovv and Stealthy Enemy: Hovv HIV Remains Latent
Studies in the Baltimore lab aim to understand various aspects of latency
the ability of HIV to remain silently hidden within cells

M

ost interactions between
virus and host occur rapid
ly. Within a few days or
months of being infected, people in
whom a particular virus proves path
ogenic have usually either success
fully combated the virus or-occa
sionally-succumbed to it.
But infection with HIV is differ
ent. During the course of AIDS, a
person initially experiences a brief
period of illness with certain symp
toms (such as fever, chills, and
malaise) and shows certain measur
able signs (such as a dramatic
increase of virus in the blood and a
decrease of CD4 T cells). Then,
although a slow decline of helper T
cells may sometimes continue, the
symptoms disappear, the blood's
viral load abates, and the person
usually stays well for a few years, a
decade, or in rare cases even longer.

Eventually, though, the virus makes
itself felt once again. The CD4 T cell
count plummets, the viral load in the
blood soars, and the rare cancers or
opportunistic infections that will ulti
mately prove fatal set in.
This typical course of disease,
which includes the period of well
being called "clinical latency," is by
now well established, but the molec
ular and cellular events underlying 'it
are not. The basis of such molecular
and cellular latency is a subject of
study in the lab of David Baltimore,
a virologist who earned his Ph.D. at
Rockefeller and later served as its
president.
Baltimore has long had an inter
est in retroviruses in general, and
HIV in particular. For instance, he
shared the Nobel Prize with Howard
Temin in 1975 for their independent
discoveries of reverse transcriptase,
the enzyme that turns retroviral RNA
genes into DNA. In the mid-1980s,
his lab identified NF-KB, the key pro
tein that regulates the readout of
HIV's genes into a molecular inter
mediate known as messenger RNA.
And, in the late 1980s, his lab eluci
dated the complex, two-stage
process by which some HIV proteins
are produced later than others. Only
when the later stage of protein pro
duction is finished can the virus
assemble, leave the host cell, and go
on to infect other cells.
Baltimore and his colleagues are
now using versions of the assays
they developed for these viral life
stage investigations to explore the
molecular basis of latency as it is
manifested in human disease. In one
set of studies, they found dramatic
differences between two subsets of
HIV-positive individuals, all of
whose CD4 T cell counts still looked
normal. The researchers used an
unusual treasure trove of blood sam
ples provided by the New Yor k
Basic research by Profess�r David
Baltimore (right) and Postdoctoral
Associate Kalle Saksela may yield ways
to provide more individualized treatment
for people infected with HIV.

Blood Center. A detailed medical his
tory of each donor was available, so
that molecular and clinical data
could be assessed in relation to one
another.
The scientists found that
the blood of those people whose
disease
would
progress within a
few years contained
the instruction mole
cules (messenger
RNA) needed to
produce both early
and late-stage viral
proteins, while the
blood of those who
would be long-time
survivors-staying
well 10 years or
m o r e -s h o w e d
either little or none
of these messenger
"Remolecules.
searchers have been looking hard for
a way to predict the fate of individ
ual patients," Baltimore comments.
"We're hopeful these assays can be
used to identify people who can
benefit from earlier therapeutic inter
vention."
Also yielding promising results
are the lab's studies with chim
panzees, conducted in collaboration
with a French group headed by Dr.
Marc Girard, Baltimore's first post
doctoral fellow.
Chimps can be infected with HIV,
but do not develop AIDS. So far, the
blood of the animals under study by
the Baltimore team looks like the
blood of human long-term survivors:
that is, it harbors little or no HIV
messenger RNA. But messenger RNA
can be found in the animals' lymph
nodes-a significant finding in view
of recent reports that the lymphatic
tissue of humans sequesters HIV
(and so may serve as a reservoir)
during clinical latency. Thus, the

The typical course of
infection with HIVwhich includes the period
of well-being called
"clinical latency"-is
by now well established,
but the cellular events
underlying it are not.

chimp may turn out to provide what
has long been missing in HIV stud
ies-a good animal model for afleast
some stages of the human disease.
In addition to their studies of
humans and chimpanzees, the
researchers are conducting investiga
tions using two test-tube models of
cellular latency. This research indi
cates that more than one cellular

mechanism might maintain latency
on the molecular level, including a
hitherto unidentified cellular factor.
Baltimore and his colleagues plan to
explore how these test-tube models
might relate to human infection with
HIV. The researchers hope these
studies will eventually result in ways
to bolster natural mechanisms that
maintain latency.

'Natural Allies': Exploring the Role of Natural Antibodies
Researchers in the Allfrey lab are studying 'host factors' that may
help delay the progression to AIDS

T

In the laboratory of Professor Vincent
Allfrey (right), adjunct faculty member
Toby Rodman studies natural antibodies
to a protein made by HIV.
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he period of time between ini
tial infection with HIV and the
onset of AIDS varies greatly.
Some people become ill within a
year of infection, while others
remain asymptomatic for a decade or
longer.
Why does this disparity exist?
Investigators in the lab of Vincent
Allfrey aim to shed light on this
question. There, Toby Rodman and
colleagues are exploring the possibil
ity that "natural antibodies" are host
factors-that is, substances produced
by HIV's human "host"-that may
help retard the progression to AIDS.
Antibodies are proteins that travel
through the blood, latching on to
pathogens and facilitating their
destruction. Exquisitely sensitive and
specific to one particular pathogen,
antibodies are normally produced
after the virus or bacterium has
invaded the body. But natural anti
bodies are different: they are pro
duced by the body independently of
any challenge from a virus, bacteri
um, or other agent. These pre
formed antibodies may act as an
early defense system against infec
tious invaders. Although the exis
tence of natural antibodies has been
hypothesized for more than thirty
years, until recently they received lit
tle attention from the scientific
research community.
Rodman was not always involved
in research on natural antibodies.
Her ,initial studies focused on prota-

The period of time
between initial infec
tion with HIV and the
onset of Al OS varies
from person to person.
The existence of
"natural antibodies" to
a protein produced by
HIV may help explain
this disparity.
mine, a unique protein that packages
DNA in the nucleus of sperm cells.
Her interest in natural antibodies
arose in the early 1980s from discus
sions with the late Henry Kunkel, a
Rockefeller immunologist. At that
time, AIDS had been primarily identi
fied in the male homosexual popula
tion, and Kunkel and Rodman
hypothesized that the constituents of
semen, including sperm, might
somehow play a role in infection
with HIV. As an outgrowth of those
discussions, Rodman and her col
leagues discovered natural antibodies
to protamine.
More recently, they discovered
natural antibodies to a protein pro-

duced by HIV itself. This protein,
called Tat, plays a vital role in the
virus's ability to make more copies of
itself. Two different anti-Tat natural
antibodies have been found, each of
which targets a region that is essen
tial for the protein's function.
The anti-Tat natural antibodies are
present in the blood of all HIV-nega
tive people studied by the
researchers. They are also present, in
normal amounts, in people newly
infected with HIV. But as HIV infec
tion progresses, there is a corre
sponding decrease in anti-Tat natural
antibodies, and people with full
blown AIDS have very low levels or
none at all.
"The correlation between natural
antibody level and stage of disease
suggests that the antibodies may be
a factor that helps delay the progres
sion to AIDS," says Rodman. One
question that remains to be answered
is why the levels of these antibodies
-which start out just about the
same in all people-decline at vari
able rates in persons progressing
toward AIDS.
Another question is how the anti
bodies might work. In studies of HIV
infected cells grown in a culture dish,
Tat protein has been found in the
fluid outside the cells. A number of
research groups have speculated that
in the body, Tat protein may also
leave HIV-infected cells that are
actively producing new virus. If this
occurs, then the anti-Tat antibodies
might prevent this extracellular Tat
from entering HIV-infected cells that
are not yet producing virus and acti
vating the HIV genes that lie dormant
within them. Another possibility
is that the antibodies may have
a direct, destructive effect on the
Tat protein.
Much remains to be learned about
the significance and function of the
anti-Tat antibodies. But if they do
prove to be a factor in delaying the
progression to AIDS, their effects
might eventually be boosted or mim
icked to keep people who are infect
ed with HIV asymptomatic for a
longer time.
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Defensive Maneuvers: The Search for a Vaccine
Researchers in the Fischetti lab are exploring a novel approach for a
vaccine that homes in on sites vvhere HIV first enters the body

Professor Vincent Fischetti and
Postdoctoral Associate Donata Medaglini
are setting their sights on a vaccine that
elicits mucosal immunity.

T

welve years into the AIDS
epidemic, there is still no vac
cine against the disease. So far,
most vaccine research has been
geared toward boosting defensive
strategies that fight HIV
once it has entered the
body. But Vincent Fischetti
and his colleagues are tak
ing a different approach.
"We're targeting how to
prevent the infection from
occurring in the first place,"
he says.
The researchers have
their sights set on eliciting
a type of response called
mucosal immunity. The
mucosal surfaces lining
body cavities such as the
mouth, gut, and genital
tract provide one of the
body's first lines of
defense. Among the pro
tective factors found there are spe
cialized antibodies, known as IgA
antibodies, whose functions-though

Most vaccine research has
been geared toward boost
ing defensive strategies
that fight HIV once it has
entered the body. But a
different approach aims to
prevent infection with the
virus from occurring
in the first place.
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still incompletely known-are
believed to include preventing
pathogens from attaching to cells.
Such attachment is one of the first
steps in infection.
For many years, researchers
believed that a mucosal response ini
tiated at one site-say, by s�:allow
ing an oral vaccine-would provide
equally good protection at all mucos
a! surfaces, since the cells that pro
duce IgA antibodies travel from one
mucosal site to another in the body.
But Fischetti and others have shown
that antibody response is strongest at
the site where it is initially evoked.
These findings are essential to
work in Fischetti's lab, where one of
the goals is to devise live vaccine
vectors, or delivery systems, that
home in on the sites where a
pathogen first gains entry. These
sites vary, depending on the
pathogen.
The roots of Fischetti's research
stretch back to studies conducted by
Rockefeller investigator Rebecca
Lancefield in the first half of the cen
tury. In a monumental achievement,
she classified the multifarious strains,
or serotypes, of streptococci, a type
of gram-positive bacteria that cause a
wide range of diseases in humans
and animals. (Gram-positive bacteria
are a subset of microorganisms that
include the streptococci, staphylo
cocci, and pneumococci.)
As part of her work on "Group
A" streptococci, Lancefield discov
ered the M protein, a protein on the
bacterium's surface that contributes
to its ability to cause disease. Over
the years, more than eighty different
forms of the M protein have been
found among the various strains of
Group A strep.
Fischetti and his co-workers ana
lyzed the entire genetic and protein
structure of a number of different M
proteins. "By now, more is probably

known about this molecule than
about any other surface protein on
any other gram-positive bacterium,"
he says. For instance, the Rockefeller
researchers have learned that
although most regions of the M pro
tein vary among serotypes, some
regions are identical, or conserved.
One such conserved region is not
only identical among all M proteins,
but also among nearly all the surface
proteins of gram�positive bacteria.
This conserved region is responsible
for firmly attaching surface proteins
to the bacterial wall.
The implications of this discovery
are exciting. Using genetic engineer
ing techniques, it should now be
possible to fuse the conserved
attachment region onto virtually any
protein or protein fragment, and
then prompt that fusion protein to
become attached to the surface of
any gram-positive bacterium.
By exploiting harmless bacteria
that are normally found on specific
mucous membrane sites in the

human body, the engineered pro
teins could then be delivered exactly
where they are needed. Once at the
site, the proteins would provoke the
production of antibodies that would
Iater help protect against infection by
the pathogen that normally carries
these proteins.
In collaboration with Italian
researcher Gianni Pozzi (a former
visiting professor at Rockefeller),
Fischetti and his colleagues have
already linked a number of geneti
cally engineered proteins to a harm
less bacterium found in the mouth,
where it has evoked a strong anti
body response when given orally to
animals. Among those proteins' is
HIV's gp120 protein, which plays a
central role in the virus's ability to
link up with and infect host cells.

(See illustration, page 14.)

The scientists are now starting
experiments to attach gp120 to a
harmless bacterium normally found
in the vagina. They believe this strat
egy will prove particularly useful for

a vaccine against AIDS, since sexual
contacts are the leading cause world
wide of the transmission of HIV.
Because the bacteria carrying the
vaccine are live and continue to
propagate, one-time vaccination of
difficult-to-reach populations (such
as those in Asia and Africa) would
be possible. Moreover, the engi
neered, live bacteria would be trans
mitted through sexual contact to
those not originally vaccinated.
The res�archers' previous studies
have made them hopeful that the
vaginal vaccine will evoke not only a
strong mucosal immune response,
but also a strong systemic immune
response-one that induces the pro
duction of antibodies, known as IgG
antibodies, that travel throughout the
entire body via the blood. This "mul
tiple warhead" approach may prove
to be a real boon, given the unlikeli
hood that a mucosal immune
response will be able to prevent
every single viral particle from enter
ing the body.

.... .
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Spelling Disaster: The Readout of HIV's Genetic Code
Studies in the Roeder lab focus on the first step in the process that decodes
information stored in the genes. That step is especially complex for HIV

V

iruses differ from bacterial,
plant, and animal cells in
countless ways. But in one
fundamental respect, these entities
considered by some to be less than
alive-are identical to the most com
p lex living cells in existence: the
instructions encoded in their genes
must be transformed into the pro
teins that allow them to function. For
HIV, those proteins include the
structural proteins that shelter the
virus's genes, the envelope proteins
that help it invade human cells, and
the catalytic proteins essential for
many events throughout its life cycle.
HIV's genetic instructions are car
ried in RNA rather than DNA. An
enzyme called reverse transcriptase
copies the RNA genes into DNA,

which is then integrated as so-called
"proviral DNA" into the DNA of the
host cell (see illustration, page 18).
Once integrated, the proviral DNA
can be transmuted into protein using
the cell's own machinery. The nrst
step in this process is transcription
the readout of DNA into a molecular
intermediate called messenger RNA
(mRNA), whose information is then
"translated" into protein.
Transcription-an astoundingly
complex process-involves the inter
action of many proteins with one
another and with DNA control ele
ments located on the genes them
selves. Rockefeller investigator
Robert Roeder's pioneering research
has already elucidated many of the
molecular interactions that regulate

the complex process of transcription,
and he continues to break new
ground in understanding the tran
scription of many cellular and viral
genes, including the genes of HIV.
As part of his studies of HIV gene
regulation, Roeder and his col
leagues are investigating the function
of a protein called Tat.
Tat is a "transcription factor," a
type of protein that plays a major
role in the complex interactions
involved in transcription. Like all
other proteins, the instructions for
transcription factors are encoded by
the genes themselves. As is the case
for all viruses, HIV gene transcription
involves some transcription factors
encoded by cellular genes, and oth
ers encoded by genes of the virus.

Tat is a virally encoded transcription
factor.
A number of cell-encoded tran
scription factors can prompt HIV's
genes to be transcribed at a low
level. But Tat is required for high
levels of transcription. Once the first
rounds of HIV gene transcription
result in the production of enough
Tat protein, HIV transcription is
enhanced several hundred times.
Tat exerts its effects through a
highly unusual mechanism-one so
far seen only in the subset of retro
viruses (called lentiviruses) to which
HIV belongs. Tat interacts not with
HIV's DNA genes, but rather with
one of the very first mRNA regions
to be transcribed from that DNA.
This mRNA doubles back on itself to
form a "hairpin" structure, called
TAR, to which the Tat protein binds.
Cellular factors also must bind to
TAR in order for this "transactiva
tion" to work.
Exactly how all these molecular
interactions enhance the transcrip-

tion of HIV genes is still a matter of
much debate. Roeder and his col
leagues believe
that Tat's interaction with TAR
affects both the
rate at which tran
scription is initiat
ed, and the effi
ciency with which
it continues along
the entire length of
HIV's g enes. Re
searchers in the lab
are continuing to
tease out the
details of how TatTAR interactions
enhance HIV tran
scription. If such
interactions could
be blocked, the
transcription of
HIV genes would be dramatically
limited-and so, therefore, would
the production of the proteins HIV
needs to survive.

The instructions in
HIV's genes must be
transformed into the
proteins that allow the
virus to function.
Blocking the readout of
those instructions could
limit production of the
substances the virus
needs to survive.

A Deadly Connection: AIDS and Drug Abuse
Researchers at Rockefeller vvere among the first to vievv drug addiction
as a physical disease. Today, researchers in the Kreek lab explore
treatment for addiction, and aim to understand its biological basis

D

rug addiction is a major factor
fueling the AIDS epidemic. By
sharing needles, HIV-infected
drug users pass their infection to
others; in addition, addicts often
engage in unsafe sexual practices
that can also lead to infection. The
result of all these high-risk activities
is grimly evident in the statistics. In
New York City, for instance, intra
venous drug use is the cause of
almost half the AIDS cases reported,
and more than 85 percent of chil
dren with AIDS were infected due to
their parents' drug use.
How can this deadly connection
be broken? One way is through
effective treatment for drug abuse.
As Rockefeller investigator Mary
Jeanne Kreek explains, "With any
epidemic, you must remove the

source of infection, and a major
source of infection in AIDS is the
drug addict. That is why treatment to
end addiction is essential, both to
treat the individual, and to prevent
him or her from infecting others."
The treatment of drug addiction
has a long history at Rockefeller,
reaching back over thirty years to
the pioneering work of Professor
Emeritus Vincent Dole. Dole, the late
Marie Nyswander, and Kreek were
among the few at that time who
viewed the drug addict not as an
unsalvageable criminal but as a per
son afflicted by a physical disease.
Their groundbreaking research
showed that heroin addicts could be
successfully treated with methadone,
a long-acting opiate. As a result of
these studies, hundreds of

Professor Robert Roeder (left) and
Postdoctoral Fellow Camilo Parada study
the complicated molecula( interactions
controlling the readout of HIV's genes.
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Guest Investigator Lisa Borg (lefrj, Associate Professor Mary Jeanne Kreek (centei), and Senior Research
Associate Ann Ho study the immune responses of drug addicts in treatment versus those not in treatment.

methadone maintenance programs
were established worldwide.
The Rockefeller tradition of
addiction treat
ment and research
continues today in
the lab headed by
Kreek, which is a
National Institutes
of Health-National
Institute of Drug
Abuse Center for
Research in Addic
tion. Much of that
work has a direct
bearing on AIDS.
For instance, using
blood serum sam
ples collected and
stored as part of a

Drug addiction is a major
factor fueling the AIDS
epidemic. Treatment to
end addiction is essential,
both to treat the
individual and to pre
vent him or her from
infecting others.
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study conducted at Rockefeller,
Kreek and her colleagues were the
first to trace the advent of the HIV
epidemic among drug abusers in
New York City back to 1978. The
scientists have also documented the
effects of methadone maintenance
on HIV infection in heroin addicts.
Their 1984 studies, which have been
confirmed by other labs, showed a
dramatic impact: while approximate
ly 50 percent of hard-core heroin
addicts were HIV positive, only 9
percent of methadone-maintained
addicts tested positive-and those
were people who continued to use
cocaine intravenously.
The concept of methadone main
tenance programs has often met with
resistance, but Kreek is optimistic

that the tide is now turning. "The
AIDS epidemic has made the world
awaken to the need for effective
pharmacologic treatment of heroin
addiction," she says. "For the first
time, people are really willing to see
that methadone maintenance works."
In addition to their research on
methadone maintenance, Kreek and
her colleagues are examining other
links between AIDS and drug use, an
approach that falls naturally into
their studies of the biological bases
of addiction. One of the lab's main
goals is to learn why some people
who are exposed to a substance
become addicted, while others do
not. Says Kreek, "Provocative evi
dence suggests that there may be
inherent vulnerabilities to many
types of dependencies." For instance,
research in the lab has shown that
addiction not only to heroin, but to
cocaine and alcohol as well, may
involve perturbations in the endoge
nous opioid system. The endoge
nous opioids are a class of peptides,
or short amino acids, that are pro
duced in the brain and that play
roles in reproduction and the stress
response.
Endogenous opioids also are
involved in the complex biochemical
pathways that affect immune func
tion. Kreek and her colleagues have
been examining the immune-system
effects of drug use in HIV-negative
heroin addicts. Their results show
that untreated heroin addicts have
abnormalities in many immune-sys
tem parameters, such as natural killer
cell activity, T cell counts, and anti
body levels. These abnormalities dis
appear, however, when the addicts
are successfully treated with
methadone.
Such findings may help explain
why AIDS often progresses rapidly
in untreated heroin addicts who
become infected with HIV. They
also underline the need to make
methadone treatment available
for all heroin addicts-including
those infected with HIV-to bolster
their immune systems as much as
possible.

On the Trail of Disease: Tracking Emerging Viruses
1

1

1
1
Research by Stephen Morse explores emerging viruses -viruses1 such as
HIV # that seemingly strike out of nowhere. Better surveillance
is needed to prevent the spread of such viruses

A

decade ago, the world had
barely heard of HIV. Now, at
least fifteen million people
are infected with the virus, and two
and a half million have already died
from the syndrome it causes. Where
did HIV come from? How did it
spread so fast? Are there other
viruses like HIV out there just wait
ing to strike? These are some of the
questions that interest Rockefeller
investigator Stephen Morse.
Morse, a virologist, devotes much
of his research energies to the study
of the mouse thymic virus, a rodent
virus that shares a number of similar
ities with HIV, including its ability to
deplete CD4 T cells. But along with
his laboratory studies of how this
one particular virus acts on the mole
cular level, Morse is also pursuing
viruses in a broader context. His
quarry are "emerging viruses"-virus
es, such as HIV, that seemingly strike
out of nowhere.
His interest in emerging viruses
grew out of a chance conversation
held in the late 1980s with Joshua
Lederberg, the Nobel Prize-winning
scientist who was then Rockefeller's
president. At a faculty gathering,
Lederberg asked Morse about the
potential dangers a particular mouse
virus might pose for researchers
working with lab rodents. This initial
question grew into an interest so
deep that, soon after, Morse led a
multidisciplinary conference on
emerging viruses at the National
Institutes of Health. That conference
seeded the growth of a new consen
sus about how emerging viruses
make their mark on the world.
Most experts now agree that new
viruses do not often emerge as the
result of rapid mutations that quickly
transform relatively benign viruses
into dangerous ones. "Usually,
emerging viruses are simply existing

infections that have been introduced
from an animal population into a
human one," Morse explains. When,
for any number of reasons, the new
human host is unable to combat the
virus, the disease can rapidly
become an epidemic, which is
spread by the complex behaviors of
humans.
Take the case of HIV-2, the v;iral
strain that causes the majority of
AIDS cases in West Africa. The
genetic makeup of HIV-2 is virtually
identical to a monkey virus called
SIV. For many decades, humans in
West Africa have probably occasion
ally been infected with SIV, due to
their practices of eating monkey
meat and keeping monkeys as pets.
But demographic changes-moves to
crowded urban centers, increases in
the number of sexual partners, wider
travel, and adoption of modern med
ical practices such as the use of nee
dles-all contributed to a hastening
spread of the disease in the last
quarter of the twentieth century. The
origin of HIV-1 (the most common
cause of AIDS in Europe and the
United States) is less clear, but many
researchers believe that some other
infection of primates (perhaps chim
panzees) is the root cause.
Much can be done to prevent the
spread of viral disease, if the factors
contributing to viral emergence can
be monitored. Indeed, the need for
dramatically improved global surveil
lance was stressed by a recent report
on emerging infections sponsored by
the National Academy of Science's
Institute of Medicine. Morse, who
helped write the report, is now
spearheading efforts to implement its
recommendations.
His concern for tracking and sur
veillance of emerging viruses also
underlies the collaborative research
he is conducting with researchers

elsewhere, such as Jeffrey Laurence
of the Cornell University Medical
College, and Irwin Gelman, a former
Rockefeller postdoctoral fellow who
is now a faculty member a t the
Mount Sinai Medical Center. These
scientists were among the co-authors
of the paper that caused an interna
tional sensation during the summer
of 1992. The paper described the dis
covery of a small number of individ
uals with "AIDS-defining" illnesses
for instance, opportunistic infections
in persons with low CD4 T cell
counts-that could not be attributed
to HIV identified by any test currently in use.
The researchers' report attracted
tremendous media interest. So did a
number of papers, published about
six months later, that disputed the
idea of an "HIV-negative" AIDS.
While the press's attention to this
issue has now died down, the com
mitment of Morse and his colleagues

HIV-2, the causative virus of most cases of
AIDS in West Africa, is virtually identical to
SIV, a virus found in monkeys such as this
house pet.
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to further investigate the subject has
not. The scientists have been using
assays developed at Rockefeller by
Morse and Gelman that can detect
genetic sequences from all viruses in

"Emerging viruses" such as
HIV are usually existing
infections that have been
introduced from an animal
population into a human
one. The disease can then
rapidly become epidemic
when spread by the com
p I ex behaviors of humans.
the lentivirus subfamily, the class of
retroviruses to which HIV belongs.
The researchers believe they may
have found evidence of such gene
sequences in the blood of persons
with "HIV-negative" AIDS, and that
these patients' cases may represent
infection with a variant of HIV-1 that
less sensitive tests have failed to
identify.
"These findings are not as strange
or lt:!rid as some of the initial press
reports suggested," says Morse.
"Given the rapid mutation rate of
HIV, new variants are bound to arise,
and it seems likely that some may be
different enough to escape detection
by tests currently in use." Noting that
only a handful of cases have so far
been reported, he says, "If there is a
variant of HIV-1, its impact has clear
ly been far less dramatic than that
of the well-recognized HIV-1."
Nonetheless, Morse believes further
research into this controversial ques
tion must continue, so that tests can
be refined if necessary to help pre
vent the spread of AIDS.
Assistant Professor Stephen Morse (right)
and Assistant for Research James Sullivan
use highly sensitive assays to study the viral
"family" to which HIV belongs.

Conclusion
Research Provides
Hope for Future
AIDS is a worldwide catastrophe
whose toll will only worsen unless
ways are found to better treat it, pre
vent it, and, ultimately cure it. Until
such discoveries are made, millions
will continue to die from the disease
-often, tragically, while they are still
in the prime of life.
Many mysteries remain about
AIDS, and creative new approaches
are required to solve them. Perhaps
no institution is better poised to fos
ter such creative solutions than The
Rockefeller University. Founded
to conquer infectious diseases,
Rockefeller has always encouraged
interdisciplinary research that tran
scends rigidly defined scientific cate
gories in the quest to improve
human health. Today, Rockefeller
researchers are drawing on their his
toric expertise in a wide range of
fields such as molecular biology,
virology, immunology, and infectious
disease to meet the enormous scien
tific challenges posed by AIDS. At

the heart of much of their work is
The Rockefeller University Hospital,
a unique facility where insights
gained through basic biomedical
research can be brought to bear on
the treatment of people infected
with HIV.
Just as research about AIDS
draws on multiple disciplines, so the
results of that research promise to
shed new light on numerous scientif
ic fields. Because HIV thrives by
hijacking and subverting many nor
mal cellular functions, research into
the virus's modus operandi of neces
sity explores some of biology's most
fundamental questions, such as how
immune responses are generated
and how the readout of genes is
controlled. The results of this explo
ration promise new insight into
many diseases, including cancer and
autoimmune disease.
But the basic goal of AIDS
research is, of course, to conquer
AIDS. Drawing on their tradition of
research "Pro B o n o H u m a n i
Generi s"-for t h e good o f
humankind-scientists at Rockefeller
are aiming their sights at this goal.

Over the years, AIDS-related research at
the university has been supported by a
number of individuals, foundations,
and corporations, including Alexander
and Helene Abraham (through the
Jacob Bleibtreu Foundation, Inc.), The
Cremona Fund Inc., The Aaron
Diamond Foundation, The Irvington
Institute for Medical Research, the Abby
R. Mauze Charitable Trust, the Fannie
E. Rippel Foundation, The Starr
Foundation, and the Harry Winston
Research Foundation, Inc. Significant
support has also been provided by the
federal government through the National
Institutes of Health.
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This world map illustrates
the large portion of the
globe in which malaria is
commonly transmitted.

Scientists at Rockefeller
Advance in Struggle Against
M

alaria now affects a staggering 300 million peo
ple. Over one million, mostly children, die
from the disease every year. Others suffer from
chronic, debilitating malarial attacks, characterized by
fevers, chills, and violent shaking. While AIDS first
appeared in the 1980s, malaria has plagued the popula
tion of tropical regions for centuries. Today, malaria
is still counted among the world's deadliest diseases
and leading public health problems. Recently it has
become even more intractable due to the
Malaria now affects a development of drug-resistant strains of
the disease.
staggering 300 mil
Scientists at The Rockefeller Univer
sity
have
contributed a great deal to the
lion people. Over one
understanding of malaria, which is caused
million, mostly chil by a parasite spread from person to person
via mosquitoes. Over the last fifty years,
dren, die from the Rockefeller
scientists have tested new anti
disease· every year. malarial drugs, investigated the parasite's
life cycle, discovered groundbreaking new
research methods, and worked on the devel
opment of an experimental vaccine. This work may ulti
mately help save countless lives.

World War II: Malaria Research
for Their Country
Parasitologist William Trager arrived at
Rockefeller in 1933 after graduating with a doctorate
from Harvard University. In his initial studies of malar
ia, he provided the first direct evidence that lack of cer
tain nutrients increases susceptibility to the illness. He
Mika Ono Benedyk is a writer and editor in The
Rockefeller University Public Affairs Office.
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by Mika Ono Benedyk
had just begun this work, however, when World War II
broke out.
The U.S. Army was in desperate need of specialists
in malaria, as the disease threatened to incapacitate
American troops posted in the South Pacific. To make
matters worse, the Japanese controlled supplies of qui
nine, the drug of choice at that time, which
was harvested from cinchona tree plantations in
parts of Asia.
Trager and two of his Rockefeller colleagues, virol
ogist Frederick Bang and parasitologist Malcolm
Ferguson, enlisted. They were posted in a special med
ical unit in Australia whose mission was to test a new
antimalarial drug. The drug, called Atabrine, was devel
oped by the Germans in 1932. Preliminary work by the
U.S. Army suggested that Atabrine could be used safely
as a suppressant drug.
Members of this unit administered Atabrine to
malaria sufferers in the recommended dosages-one
tablet a day, six days a week-and followed the patients'
blood levels. The first subjects, men who had been
fighting in New Guinea, were having an average of four
attacks of malaria per year. Atabrine stopped the attacks
completely. Further trials in Rockhampton with hun
dreds of men confirmed that the drug was a remarkably
effective one: as long as the soldiers took Atabrine, they
didn't have malarial attacks; if they stopped, symptoms
would return within a few weeks.
"One of the young men we treated in the first trials
had had some dozen attacks of malaria," said Trager.
"He was in such bad shape when we first saw him that

he needed a blood transfusion. With the help of
Atabrine he recovered and became a technician with us.
With his cooperation, we then did a little experiment.
We asked him to stop taking his Atabrine. Like clock
work, the parasites came back. We could find them in
the blood before he had any symptoms."
On the basis of this and other work, the suppres
sant Atabrine became the standard army requirement in
malarious regions, especially the Southwest Pacific.
According to Trager, one of the medics later said that
they had never had such a healthy army as in New
Guinea at the time.
While Atabrine was critical for American troops in
World War II, it did have one drawback that prevented

forty-eight hours-to develop fully. By that time, it has
produced about a dozen daughter parasites (called
merozoites in this stage) which then break out of the
cell to invade others.
Working with samples of the malaria parasite that
Trager personally brought back from Liberia, Trager
and Rudzinska found that about half way through this
cycle in the red blood cell, the cells develop knob-like
structures on their membranes. Further biochemical
work in the lab with Araxie Kilejian and Michael
Wallach helped show that these structures are partially
made up of a parasite-derived protein that is integrated
into the host cell.
It turns out that the lab had identified the struc-
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it from being widely used afterwards. "One reason it
works so well is that it tends to accumulate in the tis
sue," explained Trager. "It is a yellow-colored drug
with a beautiful green fluorescence. After a couple of
weeks of taking it and from then on, army personnel
developed what was known as an 'Atabrine tan.' The
skin had a peculiar yellow color, and in the sunshine,
people's ears showed a green fluorescence. Of course,
they didn't like that."

Electron Microscopy Reveals
New World
After the war, Trager returned to Rockefeller to
continue his studies of bird malaria. A few years later,
he was joined by Maria Rudzinska, a protozoologist
who was the first to apply the newly developed electron
microscope to the study of the malaria parasite.
Rudzinska's work immediately revealed a whole
new world. Long-standing mysteries such as how the
parasite feeds on red blood cells were suddenly solved
with ease. Although the fixation for the slides at that
time often revealed nothing but big holes, she was able
to see the parasite clearly the first time she tried. "In the
very first sample I looked at, I made a real discovery,"
Rudzinska said. "I could see the parasite engulfing big
pieces of the red blood cell. I could see inside the food
vacuole. It was a thrilling experience."
Electron microscopy also allowed Trager and
Rudzinska to understand how the malaria parasite
develops within the red blood cell. After invading the
cell, the parasite takes about two days-forty-four to
Rockefeller University parasitologist William Trager won worldwide
acclaim for his work on malaria, most notably for his discovery of a
method to culture the disease-causing parasite. He is shown here
with a statuette he received as the first recipient of the
Rameshwardas Birla Triennial International Award for outstanding
contributions to the field of tropical diseases.
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rnres that are responsible for much of the pathology of
severe malaria. The knoblike protrusions adhere to the
walls of capillaries in various organs, causing organ
damage. In the most serious cases, they may block capil
laries in the brain, causing cerebral malaria, which is
often fatal.
In very recent work, Dr. Irwin Sherman of the
University of California at Riverside, who was a post
doctoral fellow with Trager in the 1960s and who has
since become a leading authority on the biochemistry of
malaria parasites, has synthesized specific peptides that
interfere with this adhesion. These may provide thera
py for cerebral malaria.

Cultivation: A Major Breakthrough

In the early 1970s, the most significant roadbloc}c
to developing a malaria vaccine was the lack of any
means to culrnre the parasite.
Scientists were limited t o
working with mice, birds or
monkeys-an expensive as well
as imperfect undertaking, as
these strains of malaria differ
from those that infect humans.
Many sci en tis ts around the
world struggled to grow the
red blood cell stage of the_ par
asite in culrnre.
In 1976, Trager and his colleague James Jensen
succeeded. "Many people were trying to grow the para
sites in agitated culrnres," Trager said. "I thought that
since the affected cells are attached to the walls of the
capillaries half of the time, they are used to sitting qui
etly. So, instead of using an agitated culrnre, we created
a device where a medium flowed slowly over a settled
layer of red blood cells. Strangely enough,
it worked!"
The finding generated a great deal of excitement.
Trager and Jensen's method, which is still used today,
gave scientists a simple way to work with the malaria
parasite in the lab. Trager soon received many awards
for his work, including the Darling Medal and Prize of
the World Health Organization, the First
Rameshwardas Birla Triennial International Award of
the Medical Research Centre of the Bombay Hospital
Trust, the Leukart Medal of the German Society for
Parasitology, and the Manson Medal of the Royal
Society of Tropical Medicine and Hygiene.
The new culrnre method opened up a host of new
research possibilities. It allowed the study of malarial
drug resistance (most notably to chloroquine, a cheap
and relatively safe drug widely used to combat the dis-

Most researchers in
the field are now
optimistic that there
will be a malaria vaccine in the future.
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ease) and research into drugs that may negate this resis
tance. Some notable contributors in this area have
included Trager and one-time members of his lab,
including biochemist Bill Scheibe! (now at the
Uniformed Services University of the Health Sciences
in Bethesda, Maryland) and scientist Virendra Bhasin
(now at the University of Delhi, India).
The culrnre method also made possible a deeper
understanding of the protective effect against malaria of
the sickle hemoglobin mutation. Milton Friedman, one
of Trager's srndents, found that malaria parasites could
not develop. normally in red blood cells carrying the
sickle cell trait when these cells were exposed to rela
tively low oxygen tension such as occurs in many organs
of the body in people with the condition. This helps
explain why people with the sickle cell trait rarely suffer
from severe malaria. Malaria has supplied the evolution
ary pressure that has maintained the high prevalence of
this otherwise deleterious mutation in West Africa.
More recently, the culrnre method has facilitated
basic work using newly developed molecular techniques
on the genetics of the malaria parasite. Rockefeller
alumnus Jeffrey Ravetch, now at Memorial Sloan
Kettering Cancer Instirnte, is one of those at the fore
front of these srndies.
As hoped, the ability to culrnre the parasite has also
been invaluable in making progress toward developing
a vaccine.

Toward a Vaccine
Rockefeller investigator Margaret Perkins, a former
fellow in the Trager lab, is conducting research that
may be directly applied to a future vaccine against
malaria. Examining the biochemistry of the organism,
Perkins has identified several proteins on the parasite's
surface that enable it to bind to, and enter, the
red blood cell, as well as several other proteins that
are secreted into the host cell membrane, facilitating
mvas1on.
The hope is that some of these proteins-or impor
tant pieces of them-can be synthesized and used in a
vaccine to stimulate the immune system against the par
asite before it causes disease. One of the proteins
Perkins identified, MSP 1, may be tested as early as next
year in human trials. If it proves successful, it will prob
ably be used in combination with other immune-stimu
lating antigens from different stages of the parasite.
These will most likely include other proteins from the
merozoite stage, the form that invades the red blood
cell. Proteins from the sporozoite stage, the form that
travels from the site of the mosquito bite to the liver,
and the sexual stages that develop while the parasite is

within the mosquito will probably also be included.
"It had been hoped that a vaccine against the
sporozoite would be sufficient to stop development of
subsequent stages in humans, as this would be interven
tion at the first point," said Perkins. "Unfortunately, we
now realize that this is too simplistic. Escape of a few
sporozoites from the liver will result in infection. The
idea now is to develop a multiunit vaccine, made up of
antigens or pieces of antigens from all stages of the par
asite. This would block the parasite at each stage of
development.
"Most researchers in the field are now optimistic
that there will be a malaria vaccine in the future," she
continued. "People who live in endemic areas do
develop partial immunity when they reach adulthood.
This suggests that there is hope that vaccine-induced
immunity will be successful. It will be a matter of trial
and error to determine which combination of antigens
will work. Children are most at risk, so the most
important vaccine to develop is one that is effective in
early childhood."

Colombia, Ecuador, Venezuela, and Tanzania are
promising. "We are getting 40 to 66 percent protection
in field trials," said Patarroyo, whose work recently has
received a great deal of publicity.
Another advantage of the vaccine is that it is cheap.
A three-dose series �osts thirty cents, "less than the
price of a Coca-Cola," Patarroyo noted. Even less
developed countries may be able to afford mass immu
nization if the vaccine proves feasible.
Although Patarroyo's vaccine will not eliminate
malaria, it may prove to be one important victory in
humankind's long war against infectious disease.

Clinical Trials
While work continues on potential vaccine com
ponents, one experimental vaccine, developed by a
Rockefeller adjunct faculty member, Manuel E.
Patarroyo, has come far enough along to be tested in
clinical trials.
Patarroyo, now head of the Institute of
Immunology of the San Juan de Dios Hospital in his
native Colombia, took a unique approach to making
the vaccine. Virtually all vaccines to date, including
those for polio, mumps, measles, and rubella, have been
fashioned from mutated disease microbes. Instead,
Patarroyo's vaccine is synthetic, consisting of four pep
tides (protein segments)-three from the merozoite
stage of the parasite and one from the sporozoite
stage-fused into a large molecule.
Patarroyo learned many of the techniques he
applied to creating the vaccine at Rockefeller, from sci
entists such as immunologist Henry Kunkel, microbiol
ogist John Zabriskie, and protein chemist Bruce
Merrifield.
"If Patarroyo's vaccine turns out to be a successful
one, it will be a good example of the kind of develop
ment that should happen more often," said Trager, who
at age eighty-three is still active in his lab. "The basic
work, namely the cultivating of the parasites and the
peptide synthesis, was done at Rockefeller, and the
putting together of a practical application was done in
the country where it was needed."
Preliminary tests of Patarroyo's vaccine in Brazil,

Margaret Perkins, a Rockefeller University investi
gator, is conducting research which may be directly
applied to a future vaccine against malaria.
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he Rockefeller University Hospital, founded in 1910
as the first clinical research center in the country,

pioneered a new kind of medical research in the United
States. Rather than serving simply as a testing site for
ideas generated in the lab, physicians were free to pursue
experiments on the fundamental roots of disease. Over
the last eight decades, the pioneering research that has
come out of The Rockefeller University Hospital has
included the discovery that genetic material is made of
DNA, the isolation and testing of natural antibodies, the
identification of specific genetic defects associated with
atherosclerosis, and the development of a highly effective
meningitis vaccine now used worldwide.
All photos are courtesy of The Rockefeller University Archives or Robert Reichert.

1993

Above, Jules Hirsch, pro

fessor and physician-in
chief, stands in front of a
portrait of Rufus Cole,
the first physician-in
chief of the hospital.
Hirsch directs a laborato
ry that studies energy
metabolism in man.

1923
Right, Rockefeller
investigator Michael
Heidelberger (left) and an
unidentified technician
work in the laboratory of
Donald Van Slyke. Van
Slyke brought a chemical
approach to the study of
human disease.

1992

Left, The late
Professor and Senior
Physician D. Martin
Carter and Nurse
Dorothea Caldwell
Brown speak with a
young patient. Carter
was a leading expert in
clinical and experimen
tal dermatology.

1922

Below, Rufus Cole,
who was physician-in
chief from 1910 to
1937, stands at the
bedside of one of the
hospital's patients.
Cole led important
studies on the nature of
acute lobar pneumo
nia, then one of the
nation's leading killers.

1992

Left, Professor Jan
Breslow (right) and
Postdoctoral Associate
Andrew Plump conduct
ed research that resulted
in the first transgenic
mouse model of athero
sclerosis, a major break
through in the study of
this lethal disease.
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e.1920

Right, William C.
Stadie, a Rockefeller

investigator, devel
oped a new and far
more effective way to
administer oxygen to
pneumonia patients.
This special chamber
enabled patients to
breathe a regulated
concentration of oxy
gen, greatly relieving
their respiratory dis
tress.

1918

Below, Rockefeller

investigator and
Nobel laureate Alexis
Carrel demonstrates
a new method for
treating infected
wounds. Carrel
developed the proce
dure with Henry
Dakin during World
War I, when infec
tion was a serious
problem in treating
wounded soldiers at
the front.
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1932

Above, Oswald Avery ( center

front) stands with some members
from his lab.

1993

Left, The current scientists and

staff of The Rock�f�ller
University Hospital bring the
most modern techniques to bear
on a variety of important clinical
problems. Today's research top
ics include obesity, drug addic
tion, tuberculosis, aging, menin
gitis, strep, rheumatic fever,
jaundice, psoriasis, wound heal
ing, and AIDS.

1993

Left, Professor and

Senior Physician
Ralph Steinman and
Associate Professor
Gilla Kaplan work to
elucidate the body's
complex immune
defense system which
fights disease-causing
microbes.

The·
Double
Ed g ed
Sword
T

by Susan Blum
he patients' cases were
highly unusual. All three had small-cell lung cancer,
a deadly type of tumor that rapidly kills most of its
victims and that almost never regresses, even with
aggressive treatment. Yet-in some cases with thera
py, in others without-these patients' tumors shrank
or disappeared completely. Their good luck, though,
was not unalloyed. Though their cancers resolved,
the patients were plagued by an array of neurological
symptoms, some so debilitating that they could no
longer walk or feed themselves.
Assistant Professor Robert Darnell recently
reported on these cases in the British medical jour
nal, The Lancet. They are examples of the family of
rare disorders, known as paraneoplastic neurological
syndromes, under study in his lab. Darnell, an M.D.
Ph.D., says his research into the syndromes allows
him to pursue his two compelling intellectual inter
ests-gene regulation and neurobiology-and his

I
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commitment to two scientific approaches-basic
research and clinical investigation.
As a graduate student at the Washington
University School of Medicine in St. Louis, Darnell
was intrigued by the mechanisms that control how
and when genes are transcribed (or read out) and
how their instructions are used to make proteins.
This interest may
have had a genetic
Robert Darnell's
component. Darnell's
father,
Professor
research explore$
James E. Darnell, Jr.,
1s a Rockefeller
an unusual immune
University faculty
response that
member whose re
search has elucidated
attacks cancer cells
some of the most
fundamental aspects
but also wreaks
of transcriptional
control.
havoc in the brain.
Darnell explains
that during the early
1980s, when he was earning his M.D. and Ph.D.
degrees, "studies were just starting to focus on onco
genes, genes that play central roles in signaling a cell
to differentiate or multiply in response to messages
from its environment." When these genes are mutat
ed, or when their regulation goes awry, cancer
can result.
Compelling as they were, the oncogene studies
were not the only ones that attracted Darnell's inter
est during his training. He was equally fascinated by
research in neurobiology, which was starting to
unravel the mechanisms by which neurons (nerve
cells) change in response to signaling events. "It
seemed to me that neurons and other cells in the
body might both use the same kinds of signaling
pathways for different purposes," he says. "For
instance, in most cells, these signals normally culmi
nate in regulated cell division, and their deregulation
can lead to cancer. In neurons, which do not divide,

Assistant Professor Robert Darnell inves
tigates a rare family of disorders called
the paraneoplastic neurological syn
dromes. His studies may ultimately lead
to strategies that boost the body's ability
to fight cancer.
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the functions Qf the signaling pathway are unknown,
but are perhaps related to neurons' plasticity-their
ability to change connections with other neurons in
response to messages from their environment."
To pursue the interconnections between neuro
biology and cancer biology, and to conduct both
basic research and clinical sqidies, Darnell became
an attendi'n g' neurooncologist at Memorial
Sloan-Kettering Cancer Center. There he worked
with Jerome Posner, a pioneer in ,the study of para
neoplastic neurologic syndromes�disorders that
melded Darnell's two main
interests.
In these ,diseases, small
numbers of t�mor cells of a
particular type----'-say, tumors
of the lung or· of the breast
produce a protein normally
made only by a particular type
of nerve cell-say, a Purkinje
cell in the region of the brain
called the cerebellum. This
protein production occurs due
to the expression, or activation, in the tumor cell of a gene normally turned on
only in the nerve cell.
The reason for this ectopic, or out-of-place,
gene expression is not yet understood. Perhaps it is
simply the random result of the cellular deregulation
that is cancer's hallmark. But Darnell is investigating
another possibility: that the ectopically expressed
genes normally play important regulatory roles in
nerve cells. Their aberra�t expression would give
cancer cells an advantage over normal ones, allowing
them to circumvent the controls imposed by their
own signaling networks. Darnell has termed such
genes onconeural genes.
In the tumor, the proteins encoded by
onconeural genes are perceived as foreign by the
immune system, which mounts an �ffective attack

against them. Darnell believes that the vigor and suc
cess of this defense supports the long-held p.otion
that many incipient cancers are nipped i� the bud
without our ever becoming aware that thi�y �ave
occurred.
But patients with paraneoplastic disease do
become aware that they have (or had) cancer-usual
ly not because of the cancer itself, but because of the
immune response it elicits. For some reason-per
haps a br�ak in the blood-brain barrier that normally
. screens the_ brain from many substances-antibodies
to the onconeural protein gain
access to brain cells. The
result: degenerative neurologi
cal diseases that, depending on
the neurons involved, can
impair balance, sight, motion,
memory, and a host of other
critical functions.
Why are the onconeural
proteins perceived as foreign?
"The immune system proba
bly doesn't work in the brain
exactly the same way it does in
. the rest of the body," Darnell speculates. Somehow,
this difference prevents the immune system from
- "learning" that the onconeural proteins belong to
the self. Thus, the proteins provoke an immune
response both in the tumor cells, where they do not
occur normally, and subsequently in the nerve cells,
where they are usually produced.
Just as the immunologic rationale for the attack
remains unknown, so does its mechanism. Do anti
bodies alone orchestrate the attack against onconeur
al proteins, or are immune cells known as cytotoxic
T cells also involved? Darnell is conducting studies
at The Rockefeller University Hospital to investi
gate-and design ways to modulate-the immune
attack in patients with paraneoplastic syndromes.
Darnell is also exploring the syndromes

Studies of "out-ofplace" proteins

promise insights into

cancer, the brain, and
the immune system.
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by cloning (that is, isolating) the onconeural _genes __ work may yield insights into some of neurobiology's
and characterizing the proteips for which they code. · most basic questions. And by investigating how the
immune system's response to these proteins can trig
So far, five main types of genes h_ave been cloned,
ger neuronal death, his research also holds promise
each one coding for a protein that was hitherto com
for therapeutic advances on a number of fronts.
pletely unknown. Darnell played a collaborative or
Insights gained through the clinical studies at
leading role in the work on three of the genes and
The Rockefeller University Hospital' may prove rek
their products, and believes additional ones
vant not only. to the paraneoplastic syn dromes but
may yet be found.
to other autoimmune neurologic dis:eases such as
Many of the onconeural genes now character
multiple sclerosis. Moreover, the inv�stigations into
ized give suggestive support to the hypothesis that
how im�une system
they play critical roles
respo1:1ses can trigger
in cellular regulation
neuronal death may
and signaling. For
ultimately shed light -· .
instance, one gene
on degen�rative dis
codes for a Purkinje
eases in which cell
neuronal protein with
death is triggered by
the "leucine zipper"
mechanisms other
motifs characteristic of
than direct immune
many proteins that
attack.
regulate gene tran
Darnell's studies
scription. Another
may
also advance the
gene codes for the first
fight against cancer.
identified neuron-spe
"The paraneoplastic
cific adaptin-a pro
syndromes identify
tein . that forms a
bona fide tumor anti
bridge between clathgens that are tar
rin, an! ·important cellgets of an immune
s+urfafe protein, and
response," he says.
the "taj}s" of receptors
Although
other can
that transmit signals
•
cer cells express unusual antigens (cell surface pro
coming.from outside the cell. A third gene, characteins),
none described to date elicits a stro:tJ.g enough
terized, si�ce Darnell came to Rockefeller, codes for
counterattack to thwart the cancer's $'rowth. Darnell
a pro�e�n expressed in the parts of the developing
is currently starting studies of breast tumors in
centr�l �e�ous syste� devoted to motor functions.
mice-good animal models for cancer�to learn
Prelirpin;ry experimental result� indicate that this
protein-plays a role after traJ?-�cription is completed, ·. more about how onconeural protein�.,provoke such a
vigorous immune response. A bett�r • und�rstanding
by.regulating the proGess· by �rhich newly transcribed
of this process may ultimately lead· t0 strategies
genes get turned into proteinl.
that enhance the bo?y's ability to :��nd off a wider
By inyestigating how on.coneural proteins func
range of cancers.
tion in signaling and regulqtory pathways, Darnell's

t•l
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At The Rockef€11er University Hospital,
Assistant Professor Robert Darnel I (center) ,, ,
confers with M.D.-Ph.D. students Ronald
Buckanovich and. Lori Newman.
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anvil A. Cohn, Henry G. Kunkel Professor and vice president for medical
affairs at The Rockefeller University, died of an aortic dissection June 28.
A leading cell biologist and immunologist at Rockefeller for thirty-five
years, Cohn was a pioneer in the modern study of the body's defense mechanisms
against infection. His groundbreaking experiments have shaped the modern science
of macrophages, the large white blood cells that are pivotal in inflammation and
immunity. Cohn was best known for elucidating mechanisms whereby these cells
identify, engulf, and destroy infectious microbes. His laboratory also discovered
dendritic cells and demonstrated their potency in initiating an immune response.
Cohn was committed to supporting young scientists, and scores of men and
women he trained have become leaders in universities throughout the world. He
also helped establish the university's M.D.-Ph.D. program in the early 1970s, and
his stewardship of the program continued until his death.
A graduate of Bates College (B.S., 1948) and Harvard Medical School (M.D.,
summa cum laude, 1953), Cohn came to Rockefeller in 1958 as a research associate
and assistant physician. He was appointed professor and senior physician in 1962,
the first Henry G. Kunkel Professor in 1986, and vice president for medical affairs
in 1992. From 1977 until the time of his death, Cohn was also adjunct professor of
medicine at Cornell University Medical College.
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"Zan was a prince of a man wh
fortunate enough to have know
eminent scientist, a caring phy
human being guided by a c
stance. His studies of inflammati
are classics and he used his kno
the clinic to treat infectious dis
rosy, TB, and AIDS. A man of
Zan reached out to colleagu
countries around the world. He
colleague who helped build up a
research and clinical activiti
The Rockefeller Univers
teacher, Zan was greatly admi
by his students: you can hear
speaking of his scientific acume
sensitivity to their needs, his ab·
them to become independent
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a member of the university faculty for thirty-five
years and he came to embody what this university
stands for: Pro Bono Humani Generis."
President Torsten Wiesel
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"Martin was renowned throughout the world in

the field of clinical and experimental dermatol

ogy, and he was recognized for his contribu__, . ..,._.u. .. ,�..,

of psoriasis, epidermolysis bul
·1

losa, skin cancer, and wound healing. He was a

superb clinician with profound insights and a

sense of�u,manity. Martin was an important

and integr;l merriber of our faculty, chairing

.l

t h e Executive c<Jn mittee-during a critical peri·
·.
··
d in our history\He was always ready to work
r the best interests of this institution. On the
mpus riartin, J_as l_oved and respected not

ed clinical scientist but also

anjd h.Js readiness to stand up for

i . :, I

nstdefed right. He was a generous
<

t

iods m.:!tn who enjoyed his family,
,,,,,,

)

, and civic activities. The

rsity had a very special place
have lost a very dear and

al."

D.

MARTIN

1 9 3 6

CARTER

1 9 9 3

D•

Martin Carter, Carl J. Herzog Professor of Clinical Investigation and
senior physician at The Rockefeller University, died Nov. 7 of a dissect
ing aortic aneurysm.
Renowned throughout the world in the field of clinical and experimental der
matology, Carter made many important contributions to the scientific understanding
of genetic and environmental factors that influence the development of diseases of
the skin, as well as to treatments for these conditions. Carter was a pioneer in the use
of psoralens-photosensitizing drugs-in a variety of diseases. A pioneer also in cel
lular and molecular studies on epidermolysis bullosa, a group of rare hereditary dis
orders, he was the founder of the National Epidermolysis Bullosa Registry. Carter
was also a highly respected physician and distinguished teacher.
A graduate of Dartmouth College (A.B., 1958), Harvard Medical School (M.D.,
1961), and Yale University (Ph.D., 1971), Carter came to Rockefeller in 1981 to
head the new Laboratory for Investigative Dermatology. He was previously affiliated
with Yale University School of Medicine. At the time of his death, Carter also served
as professor of dermatology and co-head of the Department of Dermatology at The
New York Hospital-Cornell Medical Center at Cornell University Medical College.
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THE BEGINNING QF A YEAR-LONG CELEBRATION·

50 YEARS OF DNA

A banner on the portico
of The Rockefeller
University Hospital
proclaims, "50 Years of
DNA: Celebrating the
Avery Laboratory and
the Discovery of the
Thread of Life."
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To

commemorate the fiftieth

·: .. anniversary of the·discovery at The R�ckefeller
Below, President
Torsten Wiesel
(right) with P�ofessor
Emeritus Maclyn
McCarty (center),
co-author of the
paper with Oswald
Avery and Colin
MacLeod, anq j ames
;
D. Watson, direc.tor
of Cold Spring
Harbor Laboratory.
"''

University that genes are made of DNA-considered by many to be the single most important
biological discovery of the twentieth century
the university .has kicked off a year-long series
of events that will run through May 1994.
"The 1944 discovery of Oswald Avery,
. Colin MacLeod, and Maclyn McCarty opened

,,,j,\

the gateway to the modern era of biology and
medicine," said President Torsten Wiesel� "_In
, ,�elebrating this historical event, we cel
ebrate

as

well

The

Rockefeller

University's enduring mission of diag
nosing and curing sickness by uncover
ing the inner secrets.of life."
The celebration was formally inau
gurated in November 1993 with a lec
ture by Nobel laureate James D .:
Watson, best known for discovering the
, double-helical structure of DNA.
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Above, Pioneering
microbiologist
Oswald A very
works in his lab,
around 1944.

AVERY CELEBRATION EVENT SCHEDULE
WEDNESDAY, FEBRUARY 2, 1994

5:00 P.M.

Public Lecture
"The Human Genome Project in Its Scientific Context"
David Botstein, Stanford University School of Medicine
THURSDAY, FEBRUARY 3, 1994

4:00 P.M.

Historical Roundtable
Discussion with key scientists active between the publication of
the 1944 Avery, MacLeod, and McCarty paper and the 1953 dis
covery of DNA's double-helical structure.
Moderator: Robert Olby, The Rockefeller University; author
of The Path to the Double Helix
Speakers: Erwin Chargaff, College of Physicians and
Surgeons of Columbia University (emeritus); Seymour S. Cohen,
SUNY at Stony Brook (emeritus); Alfre,d Day Hershey, Carnegie
Institute (former director); Rollin Hotchkiss, The Rockefeller
University (emeritus); Joshua Lederberg, The Rockefeller
University; Maclyn McCarty, The Rockefeller University
(emeritus); Norton K. Zinder, The Rockefeller University
FRIDAY, FEBRUARY 4, 1994

I

3:45 P.M.

Scientific Symposium
Leading scientists in research areas pursued by the Avery labora
tory-immunology, infectious disease, and molecular medicine.
Moderator: Emil Gotschlich, The Rockefeller University
Speakers: Robert Austrian, School of Medicine, University of
Pennsylvania; John B. Robbins, National Institutes of Child
Health and Human Development, National Institutes of Health
MONDAY, APRIL 18, 1994

6:00 P.M.

Public Lecture on Ethics and DNA Technology
Nancy Wexler, Columbia University
FRIDAY, MAY 6, 1994

3:45 P.M.

Scientific Symposium
Panel of young scientists working in key areas of DNA research at
The Rockefeller University
Moderator: Jan L. Breslow, The Rockefeller University
Speakers: To be announced.
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